The administration of active small ACE2 variants offers therapeutic potential in the prevention and treatment of acute kidney injury by directly reducing kidney RAS overactivity while retaining their systemic effect on ACE2 activity amplification. The gene discussed is ACE2; the disease is acute kidney injury.